See more : Jiangsu gdk Biotechnology Co., Ltd. (688670.SS) Income Statement Analysis – Financial Results
Complete financial analysis of Checkmate Pharmaceuticals, Inc. (CMPI) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Checkmate Pharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Crossfor Co.,Ltd. (7810.T) Income Statement Analysis – Financial Results
- InVitro International (IVRO) Income Statement Analysis – Financial Results
- China National Nuclear Power Co., Ltd. (601985.SS) Income Statement Analysis – Financial Results
- Treasure Global Inc. (TGL) Income Statement Analysis – Financial Results
- Grindrod Shipping Holdings Ltd. (GRIN) Income Statement Analysis – Financial Results
Checkmate Pharmaceuticals, Inc. (CMPI)
About Checkmate Pharmaceuticals, Inc.
Checkmate Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing novel therapeutics for the treatment of cancer. It develops CMP-001, which is in phase II clinical trial in combination with pembrolizumab to treat patients with PD-1 refractory melanoma; combination with nivolumab to treat patients with PD-1 naïve neoadjuvant melanoma; and treatment in patients with PD-1 refractory melanoma. Checkmate Pharmaceuticals, Inc. has strategic alliances with Merck KGaA and Pfizer. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts. As of May 27, 2022, Checkmate Pharmaceuticals, Inc. operates as a subsidiary of Regeneron Pharmaceuticals, Inc.
| Metric | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 45.82M | 26.72M | 24.25M | 18.17M |
| General & Administrative | 15.65M | 10.19M | 4.64M | 2.82M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 15.65M | 10.19M | 4.64M | 2.82M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 61.47M | 36.90M | 28.89M | 20.99M |
| Cost & Expenses | 61.47M | 36.90M | 28.89M | 20.99M |
| Interest Income | 100.00K | 79.00K | 197.00K | 180.00K |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 66.00K | 188.00K | 597.00K | 180.00K |
| EBITDA | -61.34M | -36.72M | -28.29M | -20.81M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -61.41M | -36.90M | -28.89M | -20.99M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 0.00 | -4.00K | 597.00K | 180.00K |
| Income Before Tax | -61.41M | -36.91M | -28.29M | -20.81M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -4.00K | 0.00 | 0.00 |
| Net Income | -61.41M | -36.91M | -28.29M | -20.81M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -6.42 | -3.86 | -3.44 | -2.53 |
| EPS Diluted | -6.42 | -3.86 | -3.44 | -2.53 |
| Weighted Avg Shares Out | 9.56M | 9.56M | 8.22M | 8.22M |
| Weighted Avg Shares Out (Dil) | 9.56M | 9.56M | 8.22M | 8.22M |
Checkmate Pharmaceuticals Announces Second Quarter 2021 Financial Results and Provides Business Update
Clinical trial programs for vidutolimod (CMP-001) in melanoma and head and neck cancer indications ongoing
Checkmate Pharmaceuticals to Present at the BTIG Virtual Biotechnology Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Checkmate Pharmaceuticals to Present at the BTIG Virtual Biotechnology Conference
Checkmate Pharmaceuticals to Present at the Jefferies 2021 Virtual Healthcare Conference
CAMBRIDGE, Mass., May 20, 2021 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals Inc. (NASDAQ: CMPI) (“Checkmate”), a clinical stage biopharmaceutical company focused on developing its proprietary technology to harness the power of the immune system to combat cancer, today announced that Barry Labinger,...
Checkmate Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Update on Recent Progress
CAMBRIDGE, Mass., May 13, 2021 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals, Inc. (NASDAQ: CMPI) (“Checkmate”), a clinical stage biopharmaceutical company focused on developing its proprietary technology to harness the power of the immune system to combat cancer, today announced first quarter...
Checkmate Pharmaceuticals Announces Clinical Supply Agreement with Regeneron to Evaluate Vidutolimod (CMP-001) in Combination with Libtayo® (cemiplimab)
CAMBRIDGE, Mass., May 10, 2021 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals, Inc. (NASDAQ: CMPI) (“Checkmate”), a clinical stage biopharmaceutical company focused on developing its proprietary technology to harness the power of the immune system to combat cancer, today announced the development...
Checkmate Pharmaceuticals to Present at the Bank of America Securities 2021 Virtual Healthcare Conference
CAMBRIDGE, Mass., April 28, 2021 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals Inc. (NASDAQ: CMPI) (“Checkmate”), a clinical stage biopharmaceutical company focused on developing its proprietary technology to harness the power of the immune system to combat cancer, today announced that Barry Labinger,...
Checkmate: Promising pDC Therapeutic Holds Triple-Digit Upside In Melanoma
Checkmate Pharmaceuticals, Inc. is a small clinical-stage biotech focused on the immune-system-based therapeutic development for combating cancer, particularly targeting TLR9 of pDCs with virus-like delivery. Checkmate Pharmaceuticals currently has one therapeutic in their pipeline known as Vidutolimod ("CMP-001"), a CPG-A...
Checkmate Pharmaceuticals Announces Initiation of Patient Dosing in Phase 2 Head and Neck Cancer Trial
CAMBRIDGE, Mass., April 19, 2021 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals Inc. (NASDAQ: CMPI) (“Checkmate”), a clinical stage biopharmaceutical company focused on developing its proprietary technology to harness the power of the immune system to combat cancer, today announced the initiation of...
Checkmate Pharmaceuticals Presents New Clinical Trial Translational Data with Vidutolimod at the 2021 American Association for Cancer (AACR) Annual Meeting
CAMBRIDGE, Mass., April 11, 2021 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals, Inc. (NASDAQ: CMPI) (“Checkmate”), a clinical stage biopharmaceutical company focused on developing its proprietary technology to harness the power of the immune system to combat cancer, today announced the presentation...
7 Beaten Down Stocks with Significant Insider Buying
Insider buying could be a bullish sign for a stock. Insiders may sell their shares for many reasons.
Source: https://incomestatements.info
Category: Stock Reports